An egg-derived sulfated N-Acetylactosamine glycan is an antigenic decoy of influenza virus vaccines

Jenna J. Guthmiller¹, Henry A. Utset¹, Carole Henry^{1†}, Lei Li¹, Nai-Ying Zheng¹, Weina Sun², Marcos Costa Vieira³, Seth Zost⁴, Min Huang¹, Scott E. Hensley⁴, Sarah Cobey³, Peter Palese², Patrick C. Wilson¹

¹Department of Medicine, Section of Rheumatology, University of Chicago, Chicago, IL 60637, USA

²Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

³Department of Ecology and Evolution, University of Chicago, Chicago, IL 60637, USA

⁴Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

Address correspondence to:

Jenna J. Guthmiller, 924 E. 57th St. BSLC R422, Chicago, IL 60637. Phone: 773-834-4418; Email:

jguthmiller@uchicago.edu

Patrick C. Wilson, 924 E. 57th St. BSLC R420, Chicago, IL 60637. Phone: 773-702-9009; Email:

wilsonp@uchicago.edu

[†]Current Address: Moderna Inc., Cambridge, MA 02139, USA

18 **Abstract**

19 Influenza viruses grown in eggs for the purposes of vaccine generation often acquire mutations during
 20 egg adaptation or possess differential glycosylation patterns than viruses circulating amongst humans.
 21 Here, we report that seasonal influenza virus vaccines possess an egg-derived sulfated N-
 22 acetylactosamine (LacNAc) that is an antigenic decoy. Half of subjects that received an egg-grown
 23 vaccine mounted an antibody response against this egg-derived antigen. Egg-binding monoclonal
 24 antibodies specifically bind viruses grown in eggs, but not viruses grown in other chicken derived cells,
 25 suggesting only egg-grown vaccines can induce anti-LacNAc antibodies. Notably, antibodies against the
 26 sulfated LacNAc utilized a restricted antibody repertoire and possessed features of natural antibodies,
 27 as most antibodies were IgM and have simple heavy chain complementarity determining region 3. By
 28 analyzing a public dataset of influenza virus vaccine induced plasmablasts, we discovered egg-binding
 29 public clonotypes that were shared across studies. Together, this study shows that egg-grown vaccines
 30 can induce antibodies against an egg-associated glycan, which may divert the host immune response
 31 away from protective epitopes.

32 Introduction

33 Influenza viruses have been historically grown in embryonated chicken eggs as a way to culture
 34 large quantities of virus, and as a result, most influenza virus vaccines are still generated using viruses
 35 grown in eggs. However, this process has the potential to change the immunogenicity of the virus, as the
 36 viruses may mutate their major surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) to
 37 increase infectivity in eggs (1-5). Moreover, influenza viruses grown in eggs are often less immunogenic
 38 than viruses grown in mammalian cells (6-8) and have been shown to be less effective than mammalian
 39 cell-based influenza vaccines and recombinantly expressed HA vaccines (9, 10). Due to the inherent
 40 difference in avian versus mammalian glycosylation patterns, egg-grown vaccines may lack certain
 41 glycans that would be expressed on influenza viruses transmitted among humans. Notably, vaccine
 42 effectiveness against recent H3N2 viruses may be reduced due to the lack of a glycan on HA of H3N2
 43 viruses grown in eggs (1).

44 However, slight differences in viral sequences and glycosylation patterns of HA do not fully explain
 45 why vaccine effectiveness is low, as serum from vaccinated subjects can have similar antibody titers
 46 against egg adapted strains and viruses circulating in the population (11). Poor immunogenicity against
 47 HA may explain reductions in vaccine effectiveness rather than egg-adapted mutations (11). It is possible
 48 that egg-grown vaccines are preferentially inducing antibodies against non-protective viral antigens,
 49 therefore reducing vaccine effectiveness and seroconversion against protective epitopes on the HA head
 50 domain. Similar to subjects receiving egg-grown vaccines (12, 13), HA-reactive antibodies induced by
 51 vaccines grown in mammalian cells and insect cells largely induced antibodies mostly targeting the head
 52 domain of HA (14). However, whether different vaccine platforms induced antibodies against distinct
 53 influenza virus antigens, other than HA, is not known. As internal antigens, such as the nucleoprotein
 54 (NP), were shown to provide limited protection against infection (12), it remains to be determined how
 55 different vaccine formulations drive antibodies against distinct protective and non-protective antigens.

56 To address whether these egg-grown influenza virus vaccines induced antibodies against
 57 potentially non-protective antigens, we cloned monoclonal antibodies (mAbs) from plasmablasts (PBs),
 58 a transient antibody secreting cell population, isolated from subjects following vaccination with egg-grown

59 influenza virus vaccines. We show that 50% of subjects generated a PB response against an egg-derived
60 antigen present in the vaccine. Subjects that mounted a response against the egg-associated antigen
61 seroconverted against HA to similar levels as subjects that did not mount an anti-egg response, indicating
62 egg-grown vaccines did not reduce overall secreted antibody responses against HA. We identified that
63 the egg-derived antigen was a sulfated N-acetylglucosamine (LacNAc) glycan and was only present in
64 viruses grown in the allantois of eggs, but not in viruses grown in chicken embryo cell line or primary
65 chicken fibroblasts. Antibodies binding the egg-derived glycan utilized a restricted repertoire and
66 resembled natural antibodies, as antibodies were largely IgM and had short heavy chain complementarity
67 determining region 3 (H-CDR3). Moreover, we identified that egg-binding antibodies identified in our
68 study were public clonotypes, indicating the same antibodies were found across individual subjects that
69 had been vaccinated with an egg-grown vaccine. Together, our study shows that egg-grown vaccines
70 can induce antibodies against an egg related glycan and that these glycan-binding mAbs resemble those
71 produced by innate-like B cells.

Results

Influenza virus vaccination induces antibodies against an egg-associated antigen

To address the antigen specificity of memory B cells recalled by egg-grown influenza virus vaccines, we generated mAbs from sorted PBs 7 days following vaccination. The transient PB population are highly specific to the components of the vaccine and are recalled from pre-existing memory B cells (15-17). We focused our studies on mAbs generated from subjects following vaccination with the 2009 monovalent pandemic H1N1 inactivated influenza virus vaccine (MIV) and the 2010 trivalent inactivated influenza virus vaccine (TIV). From the vaccine induced PBs, we found that 75% of mAbs bound HA (Figure S1A and B). Notably, 27 mAbs generated from multiple subjects receiving either of the egg-grown vaccines bound all influenza virus strains tested (Figure 1A; Table S1). To confirm these mAbs were specific to influenza viruses and not an artifact of vaccine preparation in eggs, we tested mAb binding to A/California/7/2009 H1N1 virus grown in eggs or in mammalian Madin-Darby Canine Kidney (MCDK) cells. Strikingly, these mAbs only bound to A/California/7/2009 grown in eggs, but not virus propagated in mammalian cells (Figure 1B and C), indicating these broadly reactive mAbs were binding to an egg-related antigen. Moreover, these broadly reactive mAbs bound to allantoic fluid from both uninfected eggs and A/California/7/2009 H1N1 infected eggs (Figure 1D-E), indicating these mAbs were specific to an egg associated antigen.

50% of all subjects analyzed generated egg-specific antibody responses (Figure S1C), with 1 out of 5 of the subjects receiving the MIV and 6 out of 9 of subjects receiving the TIV generating an egg-specific antibody response (Table S1). Within the subjects that mounted an antibody response against this egg-derived antigen, 31% of mAbs generated specifically bound the egg-derived antigen (Figure 1F). The range of antibodies per subject ranged from 8% to 58% of isolated vaccine induced PBs (Figure 1G). Additionally, we found that subjects that had egg-reactive mAbs had a larger fold increase in serum IgG responses against uninfected allantoic fluid relative to subjects who did not have detectable mAbs against the egg-associated antigen (Figure 1H). Despite this, subjects that mounted an antibody response against the egg-associated antigen had a similar fold increase in serum IgG titers against A/California/7/2009 recombinant HA and hemagglutination inhibition (HAI) titers against

A/California/7/2009 H1N1, relative to subjects that did not generate a PB response against the egg antigen (Figure S1D-F). Together, these data indicate that some subjects following influenza virus vaccination generate an antibody response against an egg-derived antigen.

Viruses grown in allantoic fluid, but not other parts of the egg, possess the egg antigen

Starting in 2018, the United States Center for Disease Control began recommending that people with egg allergies could receive egg-grown influenza virus vaccines, suggesting the major egg allergens were removed from the vaccine (<https://www.cdc.gov/flu/prevent/egg-allergies.htm>). Although subjects within our cohorts had not experienced an allergic response to influenza virus vaccination or reported a history of egg allergies, we next tested whether the identified egg-specific mAbs could bind to more recent inactivated influenza virus vaccines grown in eggs that lack the egg allergens. Notably, the egg-specific mAbs could bind old TIVs and quadrivalent inactivated influenza virus vaccines (QIVs) to a similar degree as recent egg-grown QIVs, including the 2020 Fluarix QIV (Figure 2A), indicating the egg-specific antigen identified still persists in recent egg-grown vaccines. Additionally, some QIVs are also made from viruses grown in mammalian MDCK cells (Flucelvax) and recombinant HA generated in insect cells (Flublok). The egg-binding mAbs specifically bound to QIV viruses grown in eggs, but not viruses grown in MDCK or recombinant HA grown in insect cells (Figure 2B). We also confirmed that these egg-binding mAbs could bind other viruses grown in the allantoic fluid of eggs, as these mAbs bound as strongly to Newcastle Disease Virus grown in eggs as it did to A/California/7/2009 H1N1 grown in eggs (Figure 2C). To understand how ubiquitous the egg antigen was across chicken cell- and egg-grown vaccines, we next tested for mAb binding to other vaccines grown in chicken cells. Notably, the mumps and measles viruses of the Measles/Mumps/Rubella vaccine (MMR) are both grown in a chicken embryo cell line and the rabies virus in Rabavert is grown in primary chicken fibroblasts. As a control, we also tested the egg binding mAbs for binding to non-egg or chicken grown vaccines including the Japanese Encephalitis Virus Vaccine (Ixiaro) grown in Vero cells and the Pneumovax 23 vaccine that contains purified capsular polysaccharides from 23 distinct *Streptococcus pneumoniae* serotypes. The egg-binding mAbs only bound to vaccines grown in eggs, but not to vaccines grown in a chicken embryo cell line (MMR), primary chicken fibroblasts (Rabavert), or vaccines not produced in eggs (Ixiaro and Pneumovax 23; Figure 2D).

Together, these data reveal that the egg-associated antigen is only present in viruses grown in allantoic membrane, but not in those grown in cells isolated from chicken embryos or chicken fibroblasts.

Sulfated LacNAc is the egg-derived antigen

Egg allergies are typically caused by antibody responses against ovalbumin and ovomucoid (18), which are present in both the egg white and allantoic fluid (19, 20). However, the egg-specific mAbs did not bind to ovalbumin or ovomucoid purified from egg whites (data not shown), further indicating these mAbs were likely not specific to known egg allergens. As the antigen did not seem to be protein in nature, we next tested whether egg-binding mAbs were binding an egg-associated glycan. To test this, we deglycosylated the 2020 Fluarix QIV with a deglycosylating enzyme that removes N-linked glycans. MAbs had reduced binding to deglycosylated vaccine relative to untreated vaccine (Figure 3A). To investigate the particular glycan these mAbs were binding, we tested two mAbs (029-09 3A04 and 034-10 4G02) for binding to a glycan microarray that included 585 distinct glycans (Table S2). Both mAbs specifically bound to two sulfated LacNAc antigens, (6S)(4S)Gla β 1-4GlcNAc β and (4S)Gla β 1-4GlcNAc β (Figure 3 B and C). Treatment of purified egg-grown A/Hong Kong/485197/2014 H3N2 with a sulfate ester sulfatase significantly reduced egg-specific mAb binding (Figure 3D). Moreover, both mAbs only bound to LacNAc with a sulfate group on the hydroxyl group of 4C' of galactose, and not the hydroxyl group on 6C' of the galactose of LacNAc only, or an unsulfated LacNAc (Figure 3E and F; Table S3). Together, these data reveal that B cells induced by influenza viruses grown in eggs are binding a sulfated LacNAc.

Egg binding antibodies utilize a restricted repertoire and resemble natural antibodies

Of the egg-binding mAbs, we identified strong repertoire biases on the usage of particular heavy and light chain variable genes, with the vast majority of mAbs using VH3-07 and VL1-44 (Figure 4A and B). However, there was a lot of diversity in the H-CDR3 sequences, with no consensus on DH gene usage (Figure S2A). H-CDR3s and light chain CDR3s (L-CDR3) of egg-binding mAbs preferentially used JH4 and JL3, suggesting there was some selection for certain J genes (Figure S2B and C). Moreover, H-CDR3s of egg-binding mAbs were significantly shorter than those of vaccine-specific mAbs, whereas the L-CDR3 were significantly longer than vaccine-specific mAbs (Figure 4C). Concordantly, H-CDR3s

of egg-binding mAbs had fewer non-templated DNA insertions, or N-nucleotides, relative to vaccine-specific mAbs (Figure 4D; Figure S2D).

Analysis of clonal expansions revealed that the light chain of egg-binding mAbs across individual mAbs were highly clonal, with one light chain clone occupying over one-third of all egg-binding mAbs (Figure S2E; Table S2 and S5). Additionally, we identified 4 distinct clonal expansions, accounting for one-third of all antibodies identified (Figure S2E). However, these paired heavy and light chain clones were private, with individual clones only identified in one subject each (Table S2). PBs induced by vaccination derive from memory B cells and therefore are usually class-switched to IgG and highly mutated (17). However, egg-binding mAbs were largely IgM and had fewer mutations in the heavy chain relative to vaccine-specific mAbs (Figure 4E and F). In combination, egg-binding mAbs resemble natural antibodies produced by innate-B cells, as they express simple and short H-CDR3s, do not commonly class-switch, and have fewer mutations than vaccine-specific antibodies (21, 22). In addition, natural antibodies commonly target glycans (23) and are polyreactive (24, 25). However, egg-binding mAbs were not enriched for polyreactivity relative to vaccine-induced antibodies (Figure S2F). Despite having fewer mutations than vaccine-induced antibodies, germline (GL) reverted egg-binding mAbs had reduced binding affinity for influenza viruses grown in eggs relative to the affinity-matured (AM) mAbs generated from PBs (Figure 4G). Furthermore, we identified a clonal expansion from one subject over two influenza virus vaccine seasons (2010 TIV and 2011 TIV), with the mAbs from 2011 having higher affinity for influenza virus strains relative to the mAb from 2010 (Figure S2G-I). With the highly restricted VH/VL repertoire, short H-CDR3 sequences and reduced N-nucleotide additions, lack of class-switching, and fewer mutations, mAbs targeting sulfated LacNAc resemble natural antibodies produced by innate-like B cells (26).

Influenza virus vaccines commonly induce PBs with repertoire features of egg-binding mAbs

We next addressed whether antibodies with repertoire features of egg-binding antibodies are commonly induced after influenza virus vaccination. To dissect this question, we utilized a dataset of 7,777 B cell receptor sequences from influenza virus vaccine induced PBs from subjects that received the egg-grown 2016-2017 Fluzone QIV (27). From this dataset, we identified that 2% (175 total) of all IgG⁺ PBs

179 expressed VH3-7 with a H-CDR3 length of equal to or less than 12 amino acids that was paired with VL1-
180 44 or VL1-51 (potential egg-binding mAbs; Figure 5A). Notably, 13 out of 17 total subjects had PBs with
181 these repertoire features, occupying 0.2-17.4% of the PB response per subject (Figure 5B). Notably, this
182 dataset was specifically generated from IgG⁺ PBs. As we identified most egg-binding mAbs were IgM
183 (Figure 4E), the true number of potential egg-specific PBs induced within these subjects may be
184 substantially higher. Of the 175 heavy and light chain pairings identified, we discovered 6 public
185 clonotypes (Figure 5C; Table S5), which comprised 66.9% of the total response (117/175 paired
186 sequences). Strikingly, 3 of the public clones were shared between our study and the dataset (Figure 5C;
187 Table S5), suggesting the PBs induced in subjects in the Forgacs et al. study are specific to the egg
188 glycan. Moreover, we identified that egg-binding mAbs from our study shared at least a heavy chain or
189 light chain clone with the potential egg-binding PBs from the IgG⁺ PB dataset (Figure 5D; Table S5).
190 Together, these data suggest that PBs targeting an egg-associated glycan are commonly induced by
191 influenza virus vaccines grown in eggs.

192 Discussion

193 In this report, we identified that egg-grown viruses possess an egg-associated glycan that is
 194 immunogenic in humans. Egg-specific mAbs from PBs had evidence of prior affinity-maturation and likely
 195 derived from memory B cells that were primed by earlier vaccination with egg-grown vaccines. Moreover,
 196 most subjects within the 2010 TIV cohort had previously been vaccinated with the 2009 MIV, suggesting
 197 prior exposure to the egg antigen from the 2009 MIV generated memory B cells against this antigen.
 198 Despite some subjects mounting a response against the egg antigen, the same subjects seroconverted
 199 against the H1N1 component of the vaccine to similar levels as subjects that did not mount a response
 200 against the egg-associated antigen. Moreover, 13 out of 17 subjects from Forgacs et al. had detectable
 201 PBs with repertoire features of egg-binding mAbs. Notably, this study specifically recruited subjects that
 202 had not been vaccinated in the prior 3 seasons (27). Prior research has indicated that pre-existing serum
 203 antibodies against the strains included in the vaccine inversely correlate with the induction of PBs by
 204 vaccination (28). Therefore, subjects that mounted an anti-egg response perhaps had more B cell
 205 activation relative to subjects that did not and as a result has similar anti-HA antibody responses.

206 Despite no differences in serum antibodies against the H1N1 component of the vaccine, B cells
 207 mounted against the egg antigen may compete within germinal centers with B cells targeting protective
 208 epitopes of HA and NA, which could perturb the generation of plasma cells and memory B cells against
 209 protective epitopes. In accordance, we identified the same egg-specific clone was recalled over multiple
 210 vaccine years, suggesting subjects can repeatedly recall memory B cells against the egg-derived antigen
 211 upon repeated vaccination and further indicating egg-specific antibodies are fixed in the memory B cell
 212 repertoire. Therefore, our study suggests that repeatedly vaccinated subjects can preferentially recall
 213 memory B cells targeting irrelevant antigens associated with egg-based vaccine production, which could
 214 come at the cost of affinity-maturation and generation of plasma cells and memory B cells specific for
 215 protective epitopes that provide long-lived protection against influenza viruses. However, the precise role
 216 of egg-specific B cells competing with virus-specific B cells remains to be determined.

217 The egg-binding mAbs demonstrated features of natural antibodies produced by innate-like B
 218 cells, including their glycan specificity and repertoire features. Natural antibodies are typically raised

219 against self-antigens and evolutionarily conserved antigens such as lipids and glycans (29). In humans,
220 natural antibodies are largely elicited against glycans, including the blood group A and B antigens and
221 xenoglycans from other mammals, including the “ α -gal” epitope of galactose- α -1,3-galactose expressed
222 by most non-primate mammals (30, 31). Our studies reveals that the egg-binding antibodies were
223 specifically targeting a secondary sulfate structure of LacNAc, a common glycan found across all life
224 forms. Although the egg-binding mAbs identified in this study share key characteristics of natural
225 antibodies, the precise cellular origins of these antibodies require further analysis.

226 LacNAcs are a critical component of glycosaminoglycans (GAG), including keratan sulfate and
227 the Lewis blood group determinants (32, 33). LacNAcs are also the main ligand for galectins and mediate
228 a variety of cellular functions including cell adhesion, migration, proliferation, and apoptosis (34-36).
229 However, most mammals do not commonly sulfonate the galactose 4C' of LacNAc, and instead
230 commonly sulfate the 6C' of galactose of LacNAc and 6C' of N-acetylglucosamine of LacNAC (37).
231 Therefore, humans may mount a response specifically against the sulfated 4C' of LacNAc as it is not
232 normally sulfated in humans. However, inflammation is associated with aberrant glycosylation patterns,
233 including during cancer and autoimmunity (38). Moreover, antibodies against a sulfated 4C' LacNAc, the
234 same antigen identified in this study, were elevated in subjects with systemic sclerosis and was
235 associated with a higher prevalence of pulmonary hypertension (39). Despite these findings, the precise
236 role and function of anti-sulfated-LacNAc antibodies in the development and severity of systemic
237 sclerosis remain unknown. Furthermore, it is unknown if the antibodies induced by egg-grown influenza
238 virus vaccines and those observed during systemic sclerosis share similar repertoire features and could
239 be derived from the same B cell precursors. Lastly, it remains unknown how the 4C' sulfate LacNAc is
240 conjugated to influenza viruses grown in eggs, as a study of the glycosylation patterns of HA and NA
241 isolated from egg grown viruses did not have this glycan (40). In summary, this study identifies that
242 antibodies with features of natural antibodies can be induced against a sulfated LacNAc glycan present
243 in egg-grown vaccines.

244 **Methods**

245 **Monoclonal antibody production and sequence analysis**

246 Monoclonal antibodies were generated as previously described (15, 41, 42). Peripheral blood was
 247 obtained from each subject approximately 7 days after vaccination or infection. Lymphocytes were
 248 isolated and enriched for B cells using RosetteSep. PBs ($CD3^+CD19^+CD27^{hi}CD38^{hi}$) were single-cell
 249 sorted into 96-well plates. Immunoglobulin heavy and light chain genes were amplified by reverse
 250 transcriptase polymerase chain reaction (RT-PCR), sequenced, cloned into human IgG1, human kappa
 251 chain, or human lambda expression vectors, and co-transfected into HEK293T cells. Secreted mAbs
 252 were purified from the supernatant using protein A agarose beads. B cell clones were determined by
 253 aligning all the V(D)J sequences sharing identical progenitor sequences, as predicted by IgBLAST using
 254 our in-house software, Vgenes. For germline mAbs, germline sequences were synthesized (IdT) and
 255 cloned into antibody expression vectors, as described above.

256 **Antibody sequences and clonal analyses**

257 Previously published IgG⁺ PB sequences (27) were downloaded from NCBI GenBank (KEOV000000000
 258 and KEOU000000000). V(D)J gene usage from our study and Forgacs et al. were analyzed using IgBlast
 259 and clones were determined using our in-house software, Vgenes, based on germline sequences. For
 260 identification of egg-like mAbs from Forgacs et al. we selected B cell clones that specifically used VH3-7
 261 with a H-CDR3 of 12 or fewer amino acids that was paired with VL1-44 or VL1-51. MAb sequence
 262 alignments were made using ClustalOmega (EMBL-EBI). Non-templated nucleotide insertions at the V-
 263 D and D-J junctions of the heavy-chain gene were identified using partis v0.15.0, a Hidden Markov Model-
 264 based tool for annotating B cell receptor sequences (43). Custom code was used for processing the
 265 output (available at https://github.com/cobeylab/egg_antibodies). Visualization of clones in Figure 5D
 266 was performed in R using circlize v0.4.12 (44).

267 **Viruses, proteins, and vaccines.**

268 Influenza viruses used in all assays were grown in-house in specific pathogen free (SPF) eggs,
 269 harvested, purified, and titered. Allantoic fluid was harvested from both infected and uninfected eggs. For

MDCK cell grown virus, A/California/7/2009 H1N1 was grown in MDCK-SIAT1 cells, concentrated, and chemically inactivated with beta-propiolactone. Newcastle disease virus was grown in eggs and allantoic fluid was harvested and subsequently inactivated with beta-propiolactone, purified, and quantified. Vaccines used for mAb binding assays are outlined in Table S6. Recombinant HA (rHA) from A/California/7/2009 was expressed in HEK293T cells.

Antigen-Specific ELISA

High protein-binding microtiter plates (Costar) were coated with 8 hemagglutination units (HAU) of virus or allantoic fluid diluted 1:500 in carbonate buffer overnight at 4°C. Plates were coated with recombinant HA from A/California/7/2009 at 1 µg/ml in PBS overnight at 4°C. For testing egg-binding mAb binding to various vaccines, influenza virus vaccines were diluted to 5 µg/ml, rabavert was diluted to 0.05 UI/ml, MMR was diluted 1:100, Ixiaro (JEV) was diluted to 0.05 antigen units per ml, and Pneumovax 23 was diluted to 5 µg/ml. All tested vaccines were diluted in PBS and coated overnight at 4°C. NDV was diluted to 5 µg/ml in carbonate buffer and plates were coated overnight at 4°C.

Plates were washed the next morning with PBS 0.05% Tween and blocked with PBS containing 20% fetal bovine serum (FBS) for 1 hour at 37°C. MAbs were then serially diluted 3-fold starting at 10 µg/ml and incubated for 1.5 hour at 37°C. For serum ELISAs, serum was diluted 1:50 and further diluted 2-fold. Horseradish peroxidase (HRP)-conjugated goat anti-human IgG antibody diluted 1:1000 (Jackson Immuno Research) was used to detect binding of mAbs and serum antibodies, and plates were subsequently developed with Super Aquablue ELISA substrate (eBiosciences). Absorbance was measured at 405 nm on a microplate spectrophotometer (BioRad). To standardize the assays, control antibodies with known binding characteristics were included on each plate, and the plates were developed when the absorbance of the control reached 3.0 OD units. For the other vaccines used in Figure 2D, anti-sera against the various vaccines were used to confirm antigenicity of vaccines. Polyreactivity was determined using a polyreactive ELISA protocol, as previously described (13). Briefly, mAbs were tested for binding to 6 antigens (cardiolipin, dsDNA, flagellin, insulin, KLH, and LPS) starting at 1 µg/ml for 1.5 hours at 37°C. HRP-conjugated goat anti-human IgG antibody (Jackson Immuno Research) diluted 1:2000 in PBS/0.05% Tween/0.1mM EDTA was used to detect binding of mAbs, and

plates were subsequently developed with Super Aquablue ELISA substrate (eBiosciences). All mAbs or serum samples were tested in duplicate and all assays were performed 2-3 times. To determine mAb affinity, a non-linear regression was performed on background subtracted ODs and area under the curve (AUC) values were reported. Serum samples used in Figure 1h and Figure S1d-f are listed in Table S7.

Hemagglutination inhibition assays

For serum HAI assays, 1 part serum was treated with 3 parts Receptor Destroying Enzyme II (Seiken, Hardy Diagnostics) for 18 hours at 37°C, followed by 30 minutes at 56°C. Serum was further diluted to 1:10 with PBS and serially diluted 2-fold in PBS in duplicate in a 96-well round-bottom plate. Serially diluted serum was mixed with an equal volume of A/California/7/2009 virus (4 HAU/25 µl), and subsequently incubated at room temperature for 1 hour. 50 µl of 0.5% turkey red blood cells (Lampire Biological) were added to each well and incubated for 45 minutes at room temperature. HAI titers were determined based on the final dilution of serum for which hemagglutination inhibition was observed. All experiments were performed in duplicate twice. The fold change in HAI serum titers of post-vaccination samples relative to pre-vaccination samples are shown in Figure S1F.

Virus deglycosylation and sulfatase treatment

To deglycosylate the vaccine, 25 µg of the 2020 QIV was denatured for 10 minutes at 75°C and treated with the Protein Deglycosylation Mix II (New England Biolabs) for 30 minutes at 25°C and 1 hour at 37°C. For sulfatase treatment, A/Hong Kong/485197/2014 H3N2 virus was diluted to 160 HAU in sodium acetate (pH 5.0) and treated with 20 units/ml of sulfatase from abalone entrails (Sigma-Aldrich) for 1 hour at 37°C. As a control, equal quantities were diluted and incubated but did not receive the Deglycosylation Mix II or sulfatase enzymes and are referred to as untreated. After treatment, preparations underwent buffer exchange with PBS to remove freed glycans and sulfate groups. ELISA plates were coated at 1 µg/ml for the 2020 QIV or 8 HAU for the virus.

Glycan microarray

MAbs 029-09 3A04 and 034-10 4G02 were sent to the Protein-Glycan Interaction Resource of the Center for Functional Glycomics at the Beth Israel Deaconess Medical Center, Harvard Medical School. Printed arrays consist of 585 glycans in replicate of 6. All glycans used in the microarray are listed in Table S3

and S4. MAbs were diluted to 50 µg/ml and run on the array. The highest and lowest replicates from each set of 6 replicates were removed and the average ± S.D. was calculated from the middle 4 replicates. Structure of 6S,4S-LacNAc was made using ChemDraw JS (PerkinElmer).

Statistics

All statistical analysis was performed using Prism software (Graphpad Version 9.0). *P* values less than or equal to 0.05 were considered significant. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P < 0.0001$. Specific number of mAbs shown in each Figure are listed in the corresponding figure legends.

Subjects, cohorts, and study approval

Written informed consent was received from participants prior to inclusion in the study. All studies were performed with the approval of the University of Chicago and Emory University institutional review boards. Subjects were recruited to receive the Sanofi Pasteur 2009 pandemic H1N1 MIV or the 2010 Novartis Fluvirin TIV. Subjects labeled with SFV were recruited and vaccinated at Emory University, as previously described (45). All other subjects were recruited and vaccinated at the University of Chicago. Subject demographics are detailed in Table S1.

338 **Author contributions**

339 J.J.G. designed the study, characterized mAbs, analyzed the data, and wrote the manuscript. H.A.U.
 340 characterized mAbs. C.H. assisted with the vaccine comparison study. L.L. assisted with data analysis.
 341 N.-Y.Z. grew and purified influenza viruses. W.S. provided inactivated Newcastle Disease Virus samples.
 342 M.C.V. performed non-templated DNA sequence analyses. S.Z. and S.H. provided MDCK cell grown
 343 virus. M.H. performed mAb cloning. S.C. and P.P. provided critical feedback and discussion on the
 344 manuscript. P.C.W. supervised the work and edited the manuscript. All authors reviewed and edited the
 345 manuscript.

346 **Acknowledgments**

347 We are thankful to all subjects who participated in this study. We thank Sarah Andrews for initiating and
 348 processing samples from the 2009 MIV, 2010 TIV, and 2011 TIV cohort studies, and Jens Wrammert
 349 and Rafi Ahmed for providing samples from the 2009 MIV cohort. We thank Jamie Heimborg-Molinaro
 350 and Richard Cummings for assistance with the glycan microarray. This project was funded in part by the
 351 National Institute of Allergy and Infectious Diseases; National Institutes of Health grant numbers
 352 U19AI082724 (P.C.W.), U19AI109946 (P.C.W.), U19AI057266 (P.C.W.), P01 AI097092 (P.P.),
 353 R01AI145870-01 (P.P.), and the NIAID Centers of Excellence for Influenza Research and Surveillance
 354 (CEIRS) grant number HHSN272201400005C (P.C.W. and S.E.H.), and HHSN272201400008C (P.P.).
 355 This work was also partially supported by the National Institute of Allergy and Infectious Disease (NIAID)
 356 Collaborative Influenza Vaccine Innovation Centers (CIVIC; 75N93019C00051, P.P., P.C.W.). We thank
 357 the Protein-Glycan Interaction Resource of the CFG and the National Center for Functional Glycomics
 358 (NCFG) at Beth Israel Deaconess Medical Center, Harvard Medical School (R24 GM137763).

359 **Declaration of Interests**

360 The authors have declared no conflicts of interest.

References

1. Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. *Proc Natl Acad Sci U S A*. 2017;114(47):12578-83.
2. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. *PLoS One*. 2014;9(3):e92153.
3. Wu NC, Zost SJ, Thompson AJ, Oyen D, Nycholat CM, McBride R, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. *PLoS Pathog*. 2017;13(10):e1006682.
4. Raymond DD, Stewart SM, Lee J, Ferdman J, Bajic G, Do KT, et al. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. *Nat Med*. 2016;22(12):1465-9.
5. Garretson TA, Petrie JG, Martin ET, Monto AS, and Hensley SE. Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain. *Vaccine*. 2018;36(28):4095-101.
6. Katz JM, and Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. *J Infect Dis*. 1989;160(2):191-8.
7. Govorkova EA, Kodihalli S, Alymova IV, Fanget B, and Webster RG. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. *Dev Biol Stand*. 1999;98:39-51; discussion 73-4.
8. Gouma S, Zost SJ, Parkhouse K, Branche A, Topham DJ, Cobey S, et al. Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season. *Clin Infect Dis*. 2020;71(6):1447-53.

- 384 9. Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative Effectiveness of Cell-
385 Cultured and Egg-Based Influenza Vaccines Among Elderly Persons in the United States, 2017-
386 2018. *J Infect Dis*. 2019;220(8):1255-64.
- 387 10. Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, et al. Efficacy of
388 Recombinant Influenza Vaccine in Adults 50 Years of Age or Older. *N Engl J Med*.
389 2017;376(25):2427-36.
- 390 11. Cobey S, Gouma S, Parkhouse K, Chambers BS, Ertl HC, Schmader KE, et al. Poor
391 Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza
392 Vaccine Effectiveness in 2012-2013. *Clin Infect Dis*. 2018;67(3):327-33.
- 393 12. Dugan HL, Guthmiller JJ, Arevalo P, Huang M, Chen YQ, Neu KE, et al. Preexisting immunity
394 shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.
395 *Sci Transl Med*. 2020;12(573).
- 396 13. Guthmiller JJ, Lan LY, Fernandez-Quintero ML, Han J, Utset HA, Bitar DJ, et al. Polyreactive
397 Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza
398 Viruses. *Immunity*. 2020;53(6):1230-44 e5.
- 399 14. Henry C, Palm AE, Utset HA, Huang M, Ho IY, Zheng NY, et al. Monoclonal Antibody Responses
400 after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a
401 Comparative Study. *J Virol*. 2019;93(21).
- 402 15. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of high-
403 affinity human monoclonal antibodies against influenza virus. *Nature*. 2008;453(7195):667-71.
- 404 16. Neu KE, Guthmiller JJ, Huang M, La J, Vieira MC, Kim K, et al. Spec-seq unveils transcriptional
405 subpopulations of antibody-secreting cells following influenza vaccination. *J Clin Invest*.
406 2019;129(1):93-105.

- 407 17. Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, et al. Immune history profoundly
408 affects broadly protective B cell responses to influenza. *Sci Transl Med*. 2015;7(316):316ra192.
- 409 18. Cooke SK, and Sampson HA. Allergenic properties of ovomucoid in man. *J Immunol*.
410 1997;159(4):2026-32.
- 411 19. Cirkvencic N, Narat M, Dovc P, and Bencina D. Distribution of chicken cathepsins B and L,
412 cystatin and ovalbumin in extra-embryonic fluids during embryogenesis. *Br Poult Sci*.
413 2012;53(5):623-30.
- 414 20. Oegema TR, Jr., and Jourdain GW. Metabolism of ovomucoid by the developing chick embryo. *J*
415 *Exp Zool*. 1974;189(2):147-62.
- 416 21. Quach TD, Hopkins TJ, Holodick NE, Vuyyuru R, Manser T, Bayer RL, et al. Human B-1 and B-2 B
417 Cells Develop from Lin-CD34+CD38^{lo} Stem Cells. *J Immunol*. 2016;197(10):3950-8.
- 418 22. Griffin DO, Holodick NE, and Rothstein TL. Human B1 cells in umbilical cord and adult peripheral
419 blood express the novel phenotype CD20⁺ CD27⁺ CD43⁺ CD70. *J Exp Med*. 2011;208(1):67-80.
- 420 23. New JS, King RG, and Kearney JF. Manipulation of the glycan-specific natural antibody
421 repertoire for immunotherapy. *Immunol Rev*. 2016;270(1):32-50.
- 422 24. Casali P, Burastero SE, Nakamura M, Inghirami G, and Notkins AL. Human lymphocytes making
423 rheumatoid factor and antibody to ssDNA belong to Leu-1⁺ B-cell subset. *Science*.
424 1987;236(4797):77-81.
- 425 25. Burastero SE, Casali P, Wilder RL, and Notkins AL. Monoreactive high affinity and polyreactive
426 low affinity rheumatoid factors are produced by CD5⁺ B cells from patients with rheumatoid
427 arthritis. *J Exp Med*. 1988;168(6):1979-92.
- 428 26. Zemlin M, Bauer K, Hummel M, Pfeiffer S, Devers S, Zemlin C, et al. The diversity of rearranged
429 immunoglobulin heavy chain variable region genes in peripheral blood B cells of preterm

- 430 infants is restricted by short third complementarity-determining regions but not by limited gene
431 segment usage. *Blood*. 2001;97(5):1511-3.
- 432 27. Forgacs D, Abreu RB, Sautto GA, Kirchenbaum GA, Drabek E, Williamson KS, et al. Convergent
433 antibody evolution and clonotype expansion following influenza virus vaccination. *PLoS One*.
434 2021;16(2):e0247253.
- 435 28. Andrews SF, Kaur K, Pauli NT, Huang M, Huang Y, and Wilson PC. High preexisting serological
436 antibody levels correlate with diversification of the influenza vaccine response. *J Virol*.
437 2015;89(6):3308-17.
- 438 29. Holodick NE, Rodriguez-Zhurbenko N, and Hernandez AM. Defining Natural Antibodies. *Front*
439 *Immunol*. 2017;8:872.
- 440 30. Shilova N, Huflejt ME, Vuskovic M, Obukhova P, Navakouski M, Khasbiullina N, et al. Natural
441 Antibodies Against Sialoglycans. *Top Curr Chem*. 2015;366:169-81.
- 442 31. Galili U. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical
443 benefits. *Immunology*. 2013;140(1):1-11.
- 444 32. Caterson B, and Melrose J. Keratan sulfate, a complex glycosaminoglycan with unique
445 functional capability. *Glycobiology*. 2018;28(4):182-206.
- 446 33. Sugahara K, Yamashina I, De Waard P, Van Halbeek H, and Vliegthart JF. Structural studies on
447 sulfated glycopeptides from the carbohydrate-protein linkage region of chondroitin 4-sulfate
448 proteoglycans of swarm rat chondrosarcoma. Demonstration of the structure Gal(4-O-
449 sulfate)beta 1-3Gal beta 1-4XYL beta 1-O-Ser. *J Biol Chem*. 1988;263(21):10168-74.
- 450 34. Yang RY, Rabinovich GA, and Liu FT. Galectins: structure, function and therapeutic potential.
451 *Expert Rev Mol Med*. 2008;10:e17.
- 452 35. Vasta GR. Roles of galectins in infection. *Nat Rev Microbiol*. 2009;7(6):424-38.

453 36. Modenutti CP, Capurro JIB, Di Lella S, and Marti MA. The Structural Biology of Galectin-Ligand
454 Recognition: Current Advances in Modeling Tools, Protein Engineering, and Inhibitor Design.
455 *Front Chem.* 2019;7:823.

456 37. Greiling H. Structure and biological functions of keratan sulfate proteoglycans. *EXS.*
457 1994;70:101-22.

458 38. Reily C, Stewart TJ, Renfrow MB, and Novak J. Glycosylation in health and disease. *Nat Rev*
459 *Nephrol.* 2019;15(6):346-66.

460 39. Grader-Beck T, Boin F, von Gunten S, Smith D, Rosen A, and Bochner BS. Antibodies recognising
461 sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary
462 vascular disease. *Ann Rheum Dis.* 2011;70(12):2218-24.

463 40. She YM, Li X, and Cyr TD. Remarkable Structural Diversity of N-Glycan Sulfation on Influenza
464 Vaccines. *Anal Chem.* 2019;91(8):5083-90.

465 41. Guthmiller JJ, Dugan HL, Neu KE, Lan LY, and Wilson PC. An Efficient Method to Generate
466 Monoclonal Antibodies from Human B Cells. *Methods Mol Biol.* 2019;1904:109-45.

467 42. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, et al. Rapid generation of fully
468 human monoclonal antibodies specific to a vaccinating antigen. *Nat Protoc.* 2009;4(3):372-84.

469 43. Ralph DK, and Matsen FA. Consistency of VDJ Rearrangement and Substitution Parameters
470 Enables Accurate B Cell Receptor Sequence Annotation. *PLoS Comput Biol.*
471 2016;12(1):e1004409.

472 44. Gu Z, Gu L, Eils R, Schlesner M, and Brors B. circlize Implements and enhances circular
473 visualization in R. *Bioinformatics.* 2014;30(19):2811-2.

- 474 45. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, et al. Pandemic H1N1
 475 influenza vaccine induces a recall response in humans that favors broadly cross-reactive
 476 memory B cells. *Proc Natl Acad Sci U S A*. 2012;109(23):9047-52.

477

Figure 1

Figure 2

Figure 2: Binding is specific to viruses grown in eggs, but not chicken cells. **A**, Apparent affinity (AUC) of egg-specific mAbs binding to multiple years of influenza virus vaccines. Each line connects the same mAb binding a different vaccine (n=10 mAbs). **B**, Apparent affinity of mAbs binding to the mammalian cell grown vaccine (Flucelvax), insect cell grown vaccine (Flublok), and egg-grown vaccine (Fluzone). Each line connects the same mAb binding a different vaccine (n=11 mAbs). **C**, Egg-specific mAb binding to Newcastle Disease Virus grown in eggs and egg-grown A/California/7/2009 H1N1 virus (n=10). Each line connects the same mAb. **D**, Egg-specific mAbs (n=10) binding to the 2020/2021 Fluarix vaccine (egg-grown), measles/mumps/rubella vaccine (MMR; chicken cell line grown), rabavert (Rabies vaccine; chicken cell grown), Japanese Encephalitis Virus Vaccine (JEV, Ixiaro, Vero-cell grown), and pneumovax-23 vaccine (polysaccharides from bacteria). Data in **D** are mean $\pm$ S.D. Data in **B** were analyzed using a non-parametric Friedman Test. Data in **C** were analyzed using a two-tailed Wilcoxon matched-pairs signed rank test.

Figure 3

504

Figure 3: Egg-specific mAbs are binding to a sulfated LacNAc. **A**, Egg-specific mAb (n=24) binding to deglycosylated or untreated 2020 Fluorix QIV. **B** and **C**, 034-10 4G02 (**B**) and 029-09 3A04 (**C**) were tested for binding to glycans on a microarray. Data represent the top 50 glycan hits. **D**, Egg-specific mAb (n=26) binding to sulfatase treated or untreated A/Hong Kong/485197/2014 H3N2. **E**, 034-10 4G02 and

509 029-09 3A04 binding to non-sulfated and sulfated LacNAc glycans in glycan microarray. **F**, Structure of
 510 (6S)(4S)Galb1-4GlcNac (LacNAc). Data in **B**, **C**, and **E** are averaged RFU of 4 replicates. Each line in
 511 **A** and **D** connects the same mAb. Data in **E** are mean $\pm$ S.D. Data in **A** and **D** were analyzed using a
 512 two-tailed Wilcoxon matched-pairs signed rank test and data in **E** were analyzed using an ordinary two-
 513 way ANOVA.

Figure 4

Figure 4: Egg-binding mAbs resemble natural antibodies. **A** and **B**, VH (**A**) and VK/VL (**B**) gene usage of egg-binding mAbs. **C** and **D**, heavy chain and light chain CDR3 lengths (**C**) and non-templated DNA (N-nucleotides; **D**) of egg-binding and vaccine-specific mAb heavy chains. **E** and **F**, isotype usage (**E**) and somatic hypermutations (nucleotide mutations; nt; **F**) of egg-binding and vaccine-specific mAbs. **G**, affinity-matured (AM) 029-09 3F05, 011-10 3B01, and 034-10 4G02 were reverted back to germline (GL) and were tested for binding to egg-grown A/Uruguay/716/2007 H3N2 and A/California/7/2009 H1N1 relative to their affinity-matured (AM) counterparts. Data in **C**, **D**, **F**, and **G** are mean $\pm$ S.D. Data in **C**, **D**, and **F** were analyzed using two-tailed Mann-Whitney tests. Data in **E** were analyzed using chi-squared test.

Figure 5

Figure 5: PBs with repertoire features of egg-binding antibodies are common after vaccination. B cell receptor sequences from 7,777 IgG⁺ PBs induced by influenza virus vaccination were analyzed for repertoire features of egg-binding mAbs (VH3-7 with H-CDR3 of ≤ 12 amino acids paired with VL1-44 or VL1-51). **A** and **B**, proportion of sequences with egg-binding mAb repertoire features out of all sequences (**A**) and by subject (**B**). Red line in **B** represents the median. **C**, subject makeup (%) of public clones, including public clones specific to Forgacs et al. and shared across studies. The number above each column represents the number of clonal members per clone. **D**, circos plot of heavy and light chain clones distinct to each study (our study: blue; Forgacs et al. red) or shared across studies (purple).